#FDA approval

Poteligeo approved for mycosis fungoides and Sézary syndrome.

Azedra (iobenguane I 131) approved for pheochromocytoma or paraganglioma, tumors that can increase hormone production.

Sentimag platform helps determine if breast cancer has spread to sentinel lymph nodes.

First approval using a new FDA process to speed up cancer drug reviews.

Tibsovo led to complete remission in some people with acute myeloid leukemia.

Ribociclib now approved for pre- and perimenopausal women with HR-positive, HER2-negative breast cancer.

Androgen receptor blocker approved for cancer that progresses despite low testosterone levels.

Androgen receptor inhibitor now approved for both metastatic and nonmetastatic disease.

Decreased survival seen in some metastatic bladder cancer patients treated with pembrolizumab or atezolizumab monotherapy.

Encorafenib and binimetinib combination doubled progression-free survival in the Phase III COLUMBUS trial.

Two automated systems are now available to prevent hair loss during chemotherapy.

Pembrolizumab approved for uncommon lymphoma mostly seen in young adults.

Bevacizumab approved for women with Stage III or IV cancer after surgery.

We learn through scientific advances, but also by listening to patients.

Immunotherapy receives accelerate approval for women whose cancer progresses or relapses after chemotherapy.

Prices should be able to adjust to reflect the value in how medicines are prescribed and the outcomes they deliver.